1 |
Zhu LR, Li SS, Zheng WQ, Ni WJ, Cai M, Liu HP. Targeted modulation of gut microbiota by traditional Chinese medicine and natural products for liver disease therapy. Front Immunol 2023;14:1086078. [PMID: 36817459 DOI: 10.3389/fimmu.2023.1086078] [Reference Citation Analysis]
|
2 |
Li J, Qian H, Pi F. Effects of torularhodin against acetaminophen induced liver injury base on antioxidation, anti-inflammation and anti-apoptosis. Food Bioscience 2023. [DOI: 10.1016/j.fbio.2023.102388] [Reference Citation Analysis]
|
3 |
Zhang W, Huang M, Liu R. Editorial: Nonalcoholic fatty liver disease therapy: Exploring molecular mechanisms of well-defined composition from natural plants. Front Pharmacol 2022;13:1006750. [DOI: 10.3389/fphar.2022.1006750] [Reference Citation Analysis]
|
4 |
Cheng W, Li M, Zhang L, Zhou C, Yu S, Peng X, Zhang W, Zhang W. New roles of N6-methyladenosine methylation system regulating the occurrence of non-alcoholic fatty liver disease with N6-methyladenosine-modified MYC. Front Pharmacol 2022;13:973116. [DOI: 10.3389/fphar.2022.973116] [Reference Citation Analysis]
|
5 |
Chen H, Huang J, Ko C, Sainaghi PP. Peach Kernel Extracts Inhibit Lipopolysaccharide-Induced Activation of HSC-T6 Hepatic Stellate Cells. International Journal of Clinical Practice 2022;2022:1-6. [DOI: 10.1155/2022/4869973] [Reference Citation Analysis]
|
6 |
Li Y, Nie JJ, Yang Y, Li J, Li J, Wu X, Liu X, Chen DF, Yang Z, Xu FJ, Yang Y. Redox-Unlockable Nanoparticle-Based MST1 Delivery System to Attenuate Hepatic Steatosis via the AMPK/SREBP-1c Signaling Axis. ACS Appl Mater Interfaces 2022. [PMID: 35858286 DOI: 10.1021/acsami.2c05889] [Reference Citation Analysis]
|
7 |
Tang Z, Li L, Xia Z. Exploring Anti-Nonalcoholic Fatty Liver Disease Mechanism of Gardeniae Fructus by Network Pharmacology, Molecular Docking, and Experiment Validation. ACS Omega. [DOI: 10.1021/acsomega.2c02629] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|